Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2017-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD011639.pub2PMID 28362060PMCID PMC6464256
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Trial Sequential Analysis in systematic reviews with meta-analysis

  2017cited by this paper
• Industry sponsorship and research outcome.

  2017cited by this paper
• Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study

  2017cited by this paper
• C5L2 IN RENAL ISCHEMIA-REPERFUSION INJURY

  2016cited by this paper
• EVALUATION OF PANETH CELL ALTERATIONS AFTER INTESTINAL TRANSPLANTATION AND DURING GRAFT REJECTION

  2016cited by this paper
• Long‐term follow‐up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study

  2016cited by this paper
• Effect of donor-recipient gender mismatch in liver transplant recipients: a post-hoc analysis of the H2304 Study.

  2016cited by this paper
• Do patient characteristics influence efficacy and renal outcomes in liver transplant patients receiving everolimus?

  2016cited by this paper
• Indications for liver transplantation in adults

  2016cited by this paper
• Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study

  2016cited by this paper
• Impact on Renal Function of Stepwise Withdrawal of Tacrolimus Combined with Everolimus and EC-MPS vs Standard Treatment Combining Tacrolimus and EC-MPS in De Novo Liver Transplant Recipients: Results of the Simcer Study

  2016cited by this paper
• Renal function outcomes with prolonged-release tacrolimus according to donor age after de novo liver transplantation: a post hoc analysis from the diamond randomized, controlled trial

  2016cited by this paper
• Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study

  2015cited by this paper
• Bacillus Calmette‐Guerin therapy in non‐muscle‐invasive bladder carcinoma after renal transplantation for end‐stage aristolochic acid nephropathy

  2015cited by this paper
• EFFICACY AND SAFETY OF A COMBINATION SCHEDULE WITH ONCE-DAILY EVEROLIMUS AND ONCE-DAILY TACROLIMUS IN MAINTENANCE LIVER TRANSPLANTATION.

  2015cited by this paper
• Clinical outcomes of transplantation by MELD score: Month 12 subgroup analysis of the H2304 study.

  2015cited by this paper
• Impact of tacrolimus and mycophenolate mofetil regimen vs. a conventional therapy with steroids on cardiovascular risk in liver transplant patients

  2015cited by this paper
• Tumors With Intrahepatic Bile Duct Differentiation in Cirrhosis: Implications on Outcomes After Liver Transplantation

  2015cited by this paper
• Protein Kinase C Inhibitor Sotrastaurin in De Novo Liver Transplant Recipients: A Randomized Phase II Trial

  2015cited by this paper
• Efficacy and safety of once-daily everolimus with minimized once-daily tacrolimus after liver transplantation.

  2015cited by this paper
• Sustained virological response to antiviral therapy in a randomized trial of cyclosporine versus tacrolimus in liver transplant patients with recurrent hepatitis C infection.

  2015cited by this paper
• Highlights in basic sciences: on our way to solutions.

  2015cited by this paper
• Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial

  2015cited by this paper
• Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.

  2015cited by this paper
• Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study

  2015cited by this paper
• Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial

  2015cited by this paper
• Is Minimal, [Almost] Steroid-Free Immunosuppression a Safe Approach in Adult Liver Transplantation? Long-term Outcome of a Prospective, Double Blind, Placebo-Controlled, Randomized, Investigator-Driven Study

  2014cited by this paper
• Renal function outcomes with prolonged-release tacrolimus QD after De Novo liver transplantation for different primary diseases: Ad Hoc analysis from the DIAMOND randomized, controlled trial

  2014cited by this paper
• Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors

  2014cited by this paper
• Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods

  2014cited by this paper
• Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation

  2014cited by this paper
• Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.

  2014cited by this paper
• Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

  2014cited by this paper
• Everolimus With Reduced Tacrolimus Preserves Long-Term Renal Function in Liver Transplant Recipients: 36 and 48 Months Results From The H2304E1 Study.: Abstract# 2187

  2014cited by this paper
• A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

  2014cited by this paper
• Efficacy and Safety of Everolimus With Reduced Tacrolimus in De Novo Liver Transplant Recipients: Long-Term Results From the H2304E1 Study.: Abstract# A430

  2014cited by this paper
• Operative outcomes of adult living donor liver transplantation and deceased donor liver transplantation: A systematic review and meta‐analysis

  2014cited by this paper
• Antibody induction versus corticosteroid induction for liver transplant recipients.

  2014cited by this paper
• REFINE: A Randomized Trial Comparing Cyclosporine A and Tacrolimus on Fibrosis After Liver Transplantation for Hepatitis C

  2014cited by this paper
• Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients.

  2014cited by this paper
• De Novo Sirolimus and Reduced‐Dose Tacrolimus Versus Standard‐Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial

  2014cited by this paper
• Liver transplantation: immunosuppression and oncology

  2014cited by this paper
• Renal Function Outcomes With Tacrolimus QD After De Novo Liver Transplantation for Different Primary Diseases: Ad Hoc Analysis From The DIAMOND Randomized, Controlled Trial

  2014cited by this paper
• Impact of Anti-Thymocyte Globulin During Immunosuppression Induction in Patients with Hepatitis C After Liver Transplantation

  2014cited by this paper
• Liver transplantation: a systematic review of long‐term quality of life

  2014cited by this paper
• UK health performance: findings of the Global Burden of Disease Study 2010

  2013cited by this paper
• Diagnosis of Liver Cirrhosis in England, a Cohort Study, 1998–2009: A Comparison With Cancer

  2013cited by this paper
• 26 EVEROLIMUS-BASED IMMUNOSUPPRESSION PROVIDES SUPERIOR RENAL FUNCTION AND COMPARABLE EFFICACY VERSUS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMISED CONTROLLED TRIAL

  2013cited by this paper
• A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years.

  2013cited by this paper
• Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare‐the‐Nephron Trial

  2013cited by this paper
• Graphical Tools for Network Meta-Analysis in STATA

  2013cited by this paper
• SPIRIT 2013 statement: defining standard protocol items for clinical trials.

  2013cited by this paper
• LONG TERM-8 YEAR FOLLOW UP OF A RANDOMIZED TRIAL OF TACROLIMUS MONOTHERAPY VERSUS TRIPLE THERAPY AFTER LIVER TRANSPLANTATION FOR HCV CIRRHOSIS

  2013cited by this paper
• 180 EVEROLIMUS-BASED IMMUNOSUPPRESSION IN HCV POSITIVE DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL

  2013cited by this paper
• Efficacy of New Generation Antidepressants: Differences Seem Illusory

  2013cited by this paper
• Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes

  2013cited by this paper
• Twenty‐Year Longitudinal Follow‐Up After Orthotopic Liver Transplantation: A Single‐Center Experience of 313 Consecutive Cases

  2013cited by this paper
• Renal Function at Two Years in Liver Transplant Patients Receiving Everolimus: Results of a Randomized, Multicenter Study

  2013cited by this paper
• Trial Sequential Boundaries for Cumulative Meta-Analyses

  2013cited by this paper
• Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus–positive recipients of living donor liver transplantation

  2013cited by this paper
• Completely steroid‐free immunosuppression in liver transplantation: a randomized study

  2013cited by this paper
• Everolimus Based Immunosuppression in Hepatitis C Virus Positive De Novo Liver Transplant Recipients: 24 Month Results from a Randomized Controlled Trial

  2013cited by this paper
• Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial

  2012cited by this paper
• Evolution of Renal Function with Early Everolimus-Facilitated Reduction or Elimination of Tacrolimus in 719 De Novo Liver Transplant Recipients: 12 Month Data of the H2304 Study

  2012cited by this paper
• Sample size and power considerations in network meta-analysis

  2012cited by this paper
• How to use an article reporting a multiple treatment comparison meta-analysis.

  2012cited by this paper
• Impact of steroid-avoidance immunosuppression on long-term outcome after liver transplantation for HCV cirrhosis: the need for well documented long-term follow-up.

  2012cited by this paper
• Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies.

  2012cited by this paper
• Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.

  2012cited by this paper
• A Randomized, Controlled Study to Assess the Conversion From Calcineurin‐Inhibitors to Everolimus After Liver Transplantation—PROTECT

  2012cited by this paper
• Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool

  2012influential reference
• Influence of Reported Study Design Characteristics on Intervention Effect Estimates From Randomized, Controlled Trials

  2012cited by this paper
• mTOR inhibition in liver transplantation: how to dose for effective/safe CNI reduction?

  2012cited by this paper
• Using network meta‐analysis to evaluate the existence of small‐study effects in a network of interventions

  2012cited by this paper
• Automating network meta‐analysis

  2012cited by this paper
• Incidence, etiology and mortality of cirrhosis: a population-based cohort study

  2012cited by this paper
• Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience

  2012cited by this paper
• Everolimus With Reduced Tacrolimus Improves Renal Function in De Novo Liver Transplant Recipients: A Randomized Controlled Trial

  2012cited by this paper
• A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients

  2012cited by this paper
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

  2012cited by this paper
• Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

  2012cited by this paper
• Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

  2012cited by this paper
• Is Prevention the Best Treatment? CMV After Lung Transplantation

  2012cited by this paper
• Impact of Early Everolimus-Facilitated Reduction or Elimination of Tacrolimus on the Evolution of Renal Function in 719 De Novo Liver Transplant Recipients: 12 Month Data of the H2304 Study: 1533

  2012cited by this paper
• Long‐term follow‐up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin

  2011cited by this paper
• GRADE guidelines: 7. Rating the quality of evidence--inconsistency.

  2011cited by this paper
• Reduced‐Dose Tacrolimus with Mycophenolate Mofetil vs. Standard‐Dose Tacrolimus in Liver Transplantation: A Randomized Study

  2011cited by this paper
• Elective Liver Transplant List Mortality: Development of a United Kingdom End-Stage Liver Disease Score

  2011cited by this paper
• Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

  2011cited by this paper
• GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.

  2011cited by this paper
• NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making

  2011cited by this paper
• Heterogeneity: Subgroups, Meta-Regression, Bias And Bias-Adjustment

  2011cited by this paper
• NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials

  2011cited by this paper
• Mycophenolate Mofetil Monotherapy in Liver Transplantation: 5-Year Follow-Up of a Prospective Randomized Trial

  2011cited by this paper
• A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C

  2011cited by this paper
• Early Withdrawal of Calcineurin Inhibitors and Everolimus Monotherapy in de novo Liver Transplant Recipients Preserves Renal Function

  2010cited by this paper
• Early Steroid-Free Immunosuppression With FK506 After Liver Transplantation: Long-Term Results of a Prospectively Randomized Double-Blinded Trial

  2010cited by this paper
• Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.

  2010cited by this paper
• Long-Term Patient Outcome and Quality of Life After Liver Transplantation: Analysis of 20-Year Survivors

  2010cited by this paper
• ATG‐Fresenius Treatment and Low‐Dose Tacrolimus: Results of a Randomized Controlled Trial in Liver Transplantation

  2010cited by this paper

• Prognostic value of neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving curative therapies: a systematic review and meta-analysis

  2025cites this paper
• The role of rehabilitation across the continuum of liver disease from cirrhosis to transplantation and beyond: A narrative review

  2025cites this paper
• Oncological Complications of Liver Transplantation: A Narrative Review on De Novo and Donor-Transmitted Cancers

  2025cites this paper
• A statistical model to determine the optimal bone mineral density (BMD) screening schedule in liver transplant recipients

  2025cites this paper
• Malignancy After Living Donor Liver Transplantation.

  2024cites this paper
• Comparison of cyclosporine and tacrolimus after liver transplantation for primary biliary cholangitis: A propensity-score matched intention-to-treat registry study.

  2024cites this paper
• S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

  2024cites this paper
• Budesonide in Liver Immunology: A Therapeutic Opportunity in Liver Transplantation

  2024cites this paper
• Resveratrol attenuates cyclosporin A-induced upregulation of the thromboxane A2 receptor and hypertension via the AMPK/SIRT1 and MAPK/NF-κB pathways in the rat mesenteric artery.

  2024cites this paper
• New Scenarios in Liver Transplantation for Hepatocellular Carcinoma

  2024cites this paper
• Factors associated with operational tolerance after liver transplantation: a single center retrospective study

  2023cites this paper
• Liver Transplant as a Treatment of Primary and Secondary Liver Neoplasms.

  2023cites this paper
• Post Liver Transplant Renal Dysfunction-Evaluation, Management and Immunosuppressive Practice.

  2023cites this paper
• Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation.

  2023cites this paper
• How do network meta-analyses address intransitivity when assessing certainty of evidence: a systematic survey

  2023cites this paper
• Torquetenovirus Loads in Peripheral Blood Predict Both the Humoral and Cell-Mediated Responses to SARS-CoV-2 Elicited by the mRNA Vaccine in Liver Transplant Recipients

  2023cites this paper
• Development of a predictive nomogram for switching immunosuppressive drugs in pediatric liver transplant recipients

  2023cites this paper
• Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement

  2023cites this paper
• Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity-score matched intention-to-treat analysis.

  2023cites this paper
• Protective effect of ursodeoxycholic acid and resveratrol against tacrolimus induced hepatotoxicity

  2023cites this paper
• Anti-inflammatory IL-8 Regulation via an Advanced Drug Delivery System at the Oral Mucosa.

  2023cites this paper
• Sirolimus Attenuates Calcineurin Inhibitor-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma.

  2022cites this paper
• Recipient and Center Factors Associated With Immunosuppression Practice Beyond the First Year After Liver Transplantation and Impact on Outcomes

  2022cites this paper
• Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation

  2022cites this paper
• Investigation of the effect of video-assisted training on symptom management in patients undergoing liver transplantation

  2022influential citation
• Genetic factors underlying tacrolimus intolerance after liver transplantation

  2022cites this paper
• Protective Effect of Melatonin and Mycophenolate Mofetil Against Nephrotoxicity Induced by Tacrolimus in Wistar Rats

  2021cites this paper
• Protective effect of resveratrol on the kidney in rats under immunosuppression with tacrolimus

  2021cites this paper
• Hepatocellular Carcinoma and the Role of Liver Transplantation: A Review

  2021cites this paper
• Liver transplantation in malignant disease

  2021cites this paper
• Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma

  2021cites this paper
• Impact of biliary complications on quality of life in live-donor liver transplant recipients

  2021cites this paper
• Modelling kidney outcomes based on MELD eras - impact of MELD score in renal endpoints after liver transplantation

  2021cites this paper
• Strategies to Improve Immune Suppression Post-Liver Transplantation: A Review

  2021cites this paper
• Immunosuppression in liver and intestinal transplantation.

  2021cites this paper
• De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference.

  2021cites this paper
• Solid organ transplantations and COVID-19 disease

  2021cites this paper
• Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis

  2020influential citation
• Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma

  2020cites this paper
• 6,8-Diprenylorobol Induces Apoptosis in Human Hepatocellular Carcinoma Cells via Activation of FOXO3 and Inhibition of CYP2J2

  2020cites this paper
• Quality of life after liver transplantation.

  2020cites this paper
• Sixteen-Year Cohort of Liver Transplantation in the National Health System in Brazil: Analysis of Immunosuppression Maintenance Therapies

  2020cites this paper
• Real-World Administration of Once-Daily MeltDose® Prolonged-Release Tacrolimus (LCPT) Allows for Dose Reduction of Tacrolimus and Stabilizes Graft Function Following Liver Transplantation

  2020cites this paper
• Tacrolimus as an Effective and Durable Second-Line Treatment for Chronic Autoimmune Hepatitis: A Multicentric Study

  2020cites this paper
• Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients

  2020cites this paper
• Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma

  2019cites this paper
• mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence

  2019cites this paper
• Top research priorities in liver and gallbladder disorders in the UK

  2019cites this paper
• Area under trough concentrations of tacrolimus as a predictor of progressive renal impairment after liver transplantation.

  2019cites this paper
• Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.

  2018cites this paper
• Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis

  2018cites this paper
• Induction immunosuppression in adults undergoing liver transplantation: a network meta-analysis.

  2018cites this paper
• Traditional Chinese Medicine for Refractory Nephrotic Syndrome: Strategies and Promising Treatments

  2018cites this paper
• Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis

  2018cites this paper
• Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation

  2018cites this paper
• Reporting guideline and clinical trial registration requirements in gastroenterology and hepatology journals

  2018cites this paper
• High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation

  2018cites this paper
• Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.

  2018cites this paper
• Closed‐system drug‐transfer devices in addition to safe handling of hazardous drugs versus safe handling alone for reducing healthcare staff exposure to infusional hazardous drugs

  2017cites this paper